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Abstract: Alzheimer’s disease (AD) will affect around 115 million people worldwide by the year 
2050. It is associated with the accumulation of misfolded and aggregated proteins (β-amyloid and 
tau) in the senile plaques and neurofibrillary tangles found in the brain. Currently available drugs 
for AD only temporarily alleviate symptoms and do not slow the inevitable progression of this 
disease. New drugs are required that act on key pathologies in order to arrest or reverse cognitive 
decline. However, there has been a spectacular failure rate in clinical trials of conventional small 
molecule drugs or biological agents. Targeted nanoliposomes represent a viable and promising 
drug delivery system for AD that have not yet reached clinical trials. They are biocompatible, 
highly flexible, and have the potential to carry many different types of therapeutic molecules 
across the blood–brain barrier (BBB) and into brain cells. They can be tailored to extend blood 
circulation time and can be directed against individual or multiple pathological targets. Modi-
fications so far have included the use of brain-penetrating peptides, together with Aβ-targeting 
ligands, such as phosphatidic acid, curcumin, and a retro-inverted peptide that inhibits Aβ 
aggregation. Combining several modifications together into multifunctional liposomes is cur-
rently a research area of great interest. This review focuses on recent liposomal approaches to 
AD therapy, including mechanisms involved in facilitating their passage across the BBB, and 
the evaluation of new therapeutic agents for blocking Aβ and/or tau aggregation.
Keywords: amyloid, blood–brain barrier, cell-penetrating peptides, neurofibrillary tangles, 
senile plaques, tau
Introduction
Alzheimer’s disease (AD) affects 36 million people worldwide, and this number is set 
to rise to over 115 million by 2050, as populations age.1 AD is a neurodegenerative dis-
order that severely affects the functioning of the brain, triggering widespread neuronal 
and synaptic loss, memory impairment, and cognitive and behavioral disturbances.2 
A major hypothesis regarding the underlying cause of AD is that the progressive accu-
mulation of protein aggregates in the brain leads to neurodegeneration and dementia3 
(see Karran and de Strooper4 for a critical review). These protein aggregates include 
extracellular senile plaques, containing the β-amyloid (Aβ) peptide, and neurofibrillary 
tangles (NFTs), consisting of intra-neuronal paired helical filaments (PHFs) composed 
of hyper-phosphorylated tau protein.5 Aβ spontaneously and progressively aggregates 
to form oligomers and amyloid fibrils, with oligomers being a strong candidate for 
inducing synaptic damage and memory deficits in AD.6 However, AD is likely to be a 
multifactorial disorder, with many mechanisms, including NFT formation, contribut-
ing to neuronal cell damage.
It is well established that Aβ and tau underlie the neuropathology of AD, but 
many aspects of the neuropathogenesis of this disease remain unanswered. There is 
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good evidence that aggregation and accumulation of these 
molecules induce membrane damage and oxidative damage 
through an increase in free radical production and promotion 
of pro-inflammatory processes.7–9 NFT formation is also likely 
to interfere with axonal transport systems. The drugs currently 
available for the treatment of AD (acetylcholinesterase inhibi-
tors [AChEIs] and the NMDA antagonist memantine) do not 
target any of these underlying disease mechanisms10 and do 
not slow down the long-term progression of the disorder. 
Instead, they provide only temporarily improved cognition by 
counterbalancing neurotransmitter disturbances, in addition 
to having many limitations and side effects.11 It is therefore 
essential to develop alternative therapies, with minimal 
adverse side effects, which aim to prevent, slow or reverse 
the neurodegeneration responsible for AD. Unfortunately, 
clinical trials on 200 drugs, with different molecular targets, 
have so far failed to find a therapeutic approach that arrests 
or reverses cognitive decline in patients with AD.12–14
Any effective treatment for AD would most likely require 
the therapeutic agent concerned to be transported across the 
blood–brain barrier (BBB),15 which prevents access to the 
brain of around 98% of potential neuropharmaceuticals.16 
Liposomes are a biocompatible and highly flexible drug 
delivery system, with the potential for carrying many dif-
ferent types of bioactive molecules across the BBB. The 
therapeutic potential of liposomes was recognized shortly 
after their development in 1961, but only recently they 
have been considered as a suitable vehicle for the delivery 
of drugs that act on the central nervous system (CNS).17,18 
Their physiological composition facilitates numerous modi-
fications, in comparison with other nano-carriers. Simple 
“non-targeted” liposomes can carry a drug cargo into the 
brain (eg, via the olfactory route, see “Intranasal delivery” 
section), but modified “targeted” liposomes are required for 
effective delivery across the BBB and can also be designed 
to interact with specific molecular targets relevant to the 
treatment or prevention of AD. Liposomes can incorporate 
hydrophilic or lipophilic/hydrophobic therapeutic agents, 
where hydrophilic drugs are entrapped in the aqueous core, 
and lipophilic compounds are contained in the hydrophobic 
region of the lipid bilayer.19 Moreover, various types of 
therapeutic agent can be attached to the surface of the lipo-
somes. These various configurations can be combined to give 
a targeted multi-drug delivery system, which is particularly 
relevant for the treatment of any multifactorial disease. These 
attractive properties of liposomes have provoked an interest 
in their development as a possible new and effective therapy 
for AD. This narrative review presents our own perspective 
on recent and promising liposome approaches to AD therapy, 
including mechanisms involved in facilitating their passage 
across the BBB, and the evaluation of new therapeutic agents 
for blocking Aβ and/or tau aggregation.
The BBB
The BBB is a metabolic and transport barrier that protects 
the brain from harmful stimuli. It comprises brain capillary 
endothelial cells that are attached to each other through tight 
junctions, resulting in restricted paracellular transport.20,21 
Degrading enzymes are also present at the BBB, which 
can destroy molecules during their attempted passage into 
the brain.22 However, specific mechanisms are in place for 
the BBB transport of molecules that are essential for brain 
function,23 and these can be exploited for therapeutic drug 
delivery.
early strategies for BBB transportation
Passive diffusion permits the passage of some small lipo-
philic compounds across the BBB, such as certain amino 
acids, nucleosides, and small peptides. An early strategy 
utilized this simple mechanism by developing small lipo-
philic drugs that might pass through the endothelial cells. 
However, this excluded the vast majority of potential thera-
peutic molecules. A second approach was to develop small 
water-soluble drugs, in order to facilitate BBB transport via 
the paracellular hydrophilic diffusion pathway. However, 
most of these potential molecules could not penetrate past 
the tight endothelial cell junctions.24
Alternatives
Intracerebral or intracerebroventricular injection of drugs 
provides a strategy that avoids the BBB, but these procedures 
are highly invasive, and so are not widely used. Drugs admin-
istered by any peripheral route (eg, orally or by intravenous 
injection) will encounter the BBB.25 Alternative methods, 
such as bypassing the BBB by delivery through the olfactory 
region (eg, as a nasal spray) have some potential.26–28 Another 
strategy looks to utilize existing active BBB transport mecha-
nisms, namely carrier-mediated transcytosis (also known 
as transporter-mediated transcytosis), receptor-mediated 




Several different types of nanoparticles (eg, solid lipid, mag-
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Liposome delivery for Alzheimer’s disease
Table 1 Transport mechanisms for BBB transit and brain delivery
Transport mechanism Explanation Examples
Carrier-mediated  
transcytosis
Some essential materials required in the brain have specific  
transporters for active uptake across the BBB. Drugs can  





Receptors on the BBB endothelium can bind specifically  
with corresponding ligands and trigger internalization. Drugs  





Cell-mediated endocytosis endocytosis into endothelial cells can deliver drugs across the  
BBB. This mechanism is almost unique to the action of CPPs  
which exhibit various features to trigger transportation, and  




Adsorptive transcytosis Adsorptive-mediated targeting utilizes a modified, positively  
charged biological macromolecule for interaction with the  
negatively charged BBB, based on electrostatic attraction
Cationized bovine serum albumin109
Cationized immunoglobulins/monoclonal 
antibodies105
Abbreviations: BBB, blood–brain barrier; CPPs, cell-penetrating peptides; TAT, transactivator of transcription of human immunodeficiency virus.
as possible vectors for AD therapy. A popular strategy is 
to aim for optimum brain selectivity by targeting receptors 
or transporters that are highly expressed at the BBB, and 
improving stability, for example, by using non-natural amino 
acids in the case of peptide drugs, so that they are resistant to 
proteolysis.30 A second route considers intranasal administra-
tion of the active compounds, without any BBB interruption. 
Recent studies have begun to focus on liposomes as a possible 
carrier of drugs for the treatment of AD.31–33
BBB transport
Possible mechanisms for the transport of liposomes across 
the BBB have been highly debated.25 An initial theory was 
that the phospholipid bilayer of the liposomes on its own 
might facilitate transportation across various biological 
membranes, including the BBB, but this simple mechanism 
proved to be ineffective. Modifications proposed for enhanc-
ing the transport of liposome carriers across the BBB utilize 
the existing active transport mechanisms, involving absorp-
tive, carrier- or receptor-mediated transcytosis.34 Absorptive 
methods take advantage of the BBB’s negative charge. Cat-
ionic liposomal drug vehicles have been developed that can 
trigger cell internalization through electrostatic interactions. 
However, the nonspecific uptake of the cationic liposomes 
by peripheral tissues and their binding to serum proteins has 
meant that a toxic dose would often be required to reach 
therapeutic efficacy,35 thus limiting therapeutic potential. 
Carrier-mediated transcytosis utilizes nutrients capable of 
passing across the BBB, such as glucose and glutathione 
(GSH), that can be attached to the surface of liposomes 
and facilitate translocation.19 Ultimately, receptor-mediated 
transcytosis has great potential for success, since there are 
possibilities to target one or more of the many different recep-
tors at the BBB by using their respective ligands. Yet there 
is still substantial interest in direct penetration of the BBB 
membrane, which has been achieved largely through the use 
of cell-penetrating peptides (CPPs) (Figure 1).
Intranasal delivery
A second route involves the intranasal administration of 
liposomes. This strategy avoids the BBB by offering direct 
nose-to-brain absorption through the olfactory and trigeminal 
nerves. Liposomal encapsulation of compounds can result in 
improved penetration via this route, by protecting them from 
degradation and facilitating their transport across the mucosal 
barrier. A recent study has demonstrated effective administra-
tion of a liposome-encapsulated “β-breaker” peptide, known 
as H102, using this strategy.27 Results showed satisfactory 
drug concentrations in the brain, with limited toxicity. Thus, 




Liposome size, as well as lipid composition, affects their 
circulation in the bloodstream and uptake into the brain.36,37 
Brain delivery requires liposomes to be roughly nano- or 
microsized and consists of one or more lipid bilayers sur-
rounding an aqueous core. Only certain sizes will allow pas-
sage across the BBB for neurotherapy (such as in AD) and so 
small vesicles (100 nm and less) are often preferred. There 
are studies, however, that have shown that liposomes from 
100 to 140 nm have certain advantages, such as a longer half-
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Large nano-liposomes (250 nm in diameter) are cleared twice 
as fast as 100 nm liposomes.38 Yet, liposomes 100 nm and 
smaller have more limited storage capacity, leading to poor 
encapsulation efficiency.39 A consideration of size should be 
made based on factors such as their therapeutic application, 
encapsulation efficiency, and stability.
Lipid composition
Phospholipids commonly used in liposomes include synthetic 
lipids such as 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
and ethyl-phosphatidylcholine, or natural lipids such as 
phosphatidylcholine (PC), sphingomyelin (SP), and leci-
thin (LC). Natural lipids are at risk of contamination from 
viruses, prions, or toxins, especially if they are isolated 
from a mammalian source, for example, bovine brain. They 
are, however, cheaper in large-scale production, use fewer 
solvents and other chemicals in their extraction, and are more 
readily accepted by regulatory authorities, especially when 
derived from a non-animal (eg, plant) source. Cholesterol is 
often added to liposomes during assembly, which not only 
maintains the stability of membranes in vivo and in vitro 
but also reduces permeability and alters the structure and 
function of the vesicles.40
Aβ has been shown to insert preferentially into any 
anionic phospholipids incorporated into liposomes, which 
could have a protective effect, by removing toxic Aβ.41,42 The 
majority of treatments aimed at AD have used PEGylated 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-PEG 
2000 (DSPE) to improve circulation time (see “Stealth lipo-
somes” section), although wheat germ agglutinin, chitosan, 
silk fibroin, and polyvinyl alcohol have also been used to 
achieve similar “stealth” properties.
Figure 1 Promising liposomal BBB transport mechanisms.
Notes: Receptor-mediated transcytosis exploits receptors highly expressed at the BBB (eg, transferrin receptor). Receptor ligand binding triggers internalization and 
brain delivery. A relatively new mechanism, direct penetration, involves internalization primarily exhibited by CPPs (eg, TAT). Positively charged amino acids (+++) permit 
endocytosis by interacting with the negatively charged endothelial cell membrane (− − −). Once in the brain, multifunctional liposomes can be directed at an appropriate 
target (eg, at Aβ or tau) for AD therapy.
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Liposome delivery for Alzheimer’s disease
Liposome modifications
Liposomes can be functionalized in various ways in order 
to realize their potential as a therapeutic carrier (Figure 2). 
Modification can involve the attachment of molecules to the 
exterior, or the encapsulation of molecules internally, either 
in the aqueous core or lipid bilayers.19 Figure 2 considers 
possible modifications to liposomes that are particularly 
relevant for the treatment of AD.
Stealth liposomes
Simple liposomes are covered by plasma proteins (eg, fibrino-
gen, immunoglobulins, and complement proteins) when 
in circulation, so that a “protein corona” is formed around 
them. This leads to the activation of phagocytic systems and 
removal of these liposomes from the bloodstream.43 In order 
to improve their pharmacokinetic profile and allow longer 
time-periods in circulation, so-called “stealth” liposomes 
were developed, with polyethylene glycol (PEG), or another 
polysaccharide, incorporated into one of the lipid components 
of the liposomal membrane. PEG has high hydration, and 
this increases hydrodynamic volume and allows the forma-
tion of a water cloud around the polymer. Any hydrophilic 
molecule bound covalently to PEG also exhibits these 
properties, providing increased solubility and resistance to 
interaction with plasma proteins. Subsequently, PEGylated 
liposomes in circulation are less prone to formation of a 
protein corona, allowing dramatically improved circulation 
times. However, there is no certainty that these liposomes 
will be transported across the BBB. To provide this, fur-
ther modifications are required, often involving the use of 




The transport of liposomes across the BBB can be facilitated 
by the attachment of appropriate molecules to the lipid 
surface. One of these is GSH, an endogenous tripeptide and 
antioxidant found in almost every cell in the human body. 
Due to its essential protective role in the brain, GSH is trans-
ported actively across the BBB, via a sodium-dependent GSH 
transporter that is highly expressed on the BBB epithelium. 
However, the exact mechanism of action of this transporter 
remains unclear.45–47 “G-Technology®” is a strategy involving 
T RS Q P G
FE
DONML K J I H
Figure 2 Promising liposomal modifications for AD therapy.
Notes: These modifications improve their stability and bioavailability, aid BBB transportation, and engage therapeutic targets relevant to treatment of AD. Stability – (a) 
PeGylation. BBB transportation – (b) glutathione, (c) surface antibody, (d) PeG-peptide, (e) PeG-antibody, (f) lactoferrin, (g) glucose, (h) wheat germ agglutinin, (i) PeG-
mApoe, (j) transferrin. Targeting systems for AD – (k) phosphatidic acid, (l) PeG-curcumin, (m) lipophilic peptide, (n) lipophilic drug, (o) hydrophilic peptide, (p) hydrophilic 
drug, (q) nucleic acid.
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PEGylated liposomes with glutathione (GSH-PEG)-mediated 
delivery across the BBB into the brain, and this has shown 
some success in double transgenic APPswe/PS1ΔE9 (APP/
PS1) mice,47 but receptor saturation limits this system’s 
effectiveness.48 Additional research is required to enhance 
this strategy further.
Glucose
In a similar way to GSH, there are carrier-mediated transport 
mechanisms in place to facilitate the transport of glucose 
across the BBB, and the incorporation of glucose onto the 
liposome surface can enhance BBB delivery.30 Glucose-
modified PEGylated liposomes prepared with various PEG 
chain lengths have been tested for BBB penetration in mice. 
Results show that liposomes with shorter PEG chain lengths 
have little evidence of brain penetration, because the glu-
cose cannot interact effectively with the BBB surface, and 
therefore cannot utilize the glucose transporter. Longer PEG 
chain lengths are highly flexible and are able to fold back on 
themselves in such a way that the ability to cross the BBB 
is also impaired. Liposomes prepared with medium length 
PEG chains attached to glucose can cross the BBB more 
effectively.49 Thus, liposomal preparations with medium 
length PEGylation are likely to be the most effective method 
for utilizing glucose to enhance BBB transport.
Transferrin (Tf)
Tf is the most commonly targeted receptor (TfR), due to its 
localization on BBB endothelia. This localization is likely to 
be due to Tf’s essential role as an iron-binding blood plasma 
glycoprotein that controls the level of free iron and oxida-
tive stress in the brain, as well as in other tissues.50 Fishman 
et al demonstrated that Tf could cross the BBB via receptor-
mediated endocytosis,51 and more recent studies have shown 
that liposomes modified with Tf can also penetrate the 
BBB in vitro.52,53 However, TfR-mediated endocytosis of 
liposomes is limited due to endogenous Tf competing for 
binding to the TfR.54 This issue can in part be resolved by 
using antibodies that bind with higher affinity than Tf to TfR, 
thus avoiding this competition. Still, Tf is likely to be most 
effective as part of a highly functionalized liposome, where 
multiple modifications allow an additive increase in BBB 
transport; a view supported by recent studies.55,56
Lactoferrin (Lf)
The lactoferrin receptor (LfR), bound by Lf, is also heavily 
overexpressed on the BBB, which has led to the develop-
ment of Lf functionalized liposomes to enhance transport 
into the brain via receptor-mediated endocytosis.57 This 
delivery system has the potential to be particularly efficient, 
as the expression of the LfR on microvessels and neurons is 
increased in AD,58 allowing more effective targeting. Chen 
et al57 investigated the ability of Lf procationic liposomes (Lf-
PCLs) to cross the BBB of rodents, for potential treatment of 
AD. Lf-PCLs become positively charged upon binding to the 
Lf receptor on the BBB epithelium. This allows them to fuse 
more easily with the BBB and overcome disadvantages such 
as non-specific binding and poor stability in circulation.59
mApoe
The ApoE glycoprotein is responsible for the transport and 
delivery of cholesterol and other lipids from the plasma to 
the CNS.60 It contains a peptide binding domain that permits 
BBB transport. A peptide sequence containing this binding 
domain (mApoE) has been used to facilitate BBB transport 
in vitro.61,62 However, the success of this peptide alone to 
facilitate BBB transport is uncertain, as the BBB still limits 
the transport of ApoE, and therefore mApoE, in and out of 
the brain.63 It is likely, therefore, to be used in combination 
with other liposome modifications.
CPPs
In the last 20 years, CPPs have been identified, which are 
able to translocate across biological membranes, including 
the BBB.64 They cross in a non-toxic manner, independent 
of membrane receptors and energy, which could reduce the 
limitations of receptor saturation that have been observed 
with other methods. Most CPPs rely on positively charged 
amino acids interacting with the negatively charged mem-
brane. Arginine and to a lesser extent lysine are particularly 
effective, as they form hydrogen bonds with the negatively 
charged phosphates, which may lead to internalization. 
CPPs with different properties vary in their internalization 
mechanisms (Table 2), but remain similar in their effective 
direct penetration of cell membranes.
Among all CPPs, the HIV-1 tat (TAT) protein has been 
best described and has been used successfully for delivery of 
liposome nanoparticles into the brain.65 TAT triggers steps 
for non-specific endocytotic delivery due to ionic interactions 
between positive charges of the peptide and negative charges 
of the BBB.66 Recent studies have utilized a retro-inverted 
version of TAT, where l-amino acids are replaced with 
d-amino acids, and the sequence is reversed. This reduces 
the potential problems with TAT, such as protease degrada-
tion and poor bioavailability in vivo, but still maintains the 

































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1




Liposome delivery for Alzheimer’s disease
as polyarginines (eg, octa-arginine) and penetratin have also 
shown potential for the delivery of therapeutics directly to 
the brain in SAMP8 mice.68
Multifunctionalized liposomes
Many of the modifications discussed above are likely to 
be more effective as part of a multifunctionalized lipo-
somal system. This will include one or more molecules 
that enhance BBB transport, but most importantly, it will 
allow the incorporation of molecules that permit both BBB 
transport and targeting for AD therapy. The following are 
multifunctionalized liposomal systems that utilize some of 
the modifications discussed above and are in development 
as possible treatments for AD.
Aβ targeting
It is likely that the accumulation and aggregation of Aβ in 
the brain have an important role, directly or indirectly, in the 
induction of synaptic damage and memory deficits in AD.69,70 
The accumulation of Aβ oligomers or fibrils may be caused 
by overproduction, inefficient clearance from the brain, or 
by a combination of both of these. Effective therapeutic 
molecules can have an impact on one of these mechanisms 
to reduce Aβ burden. Many of these molecules on their own 
have low uptake across the BBB, but their incorporation into 
a multifunctionalized liposomal system can help to resolve 
this problem, allowing effective targeting to Aβ.
 mApoe-PA liposomes
Balducci et al71 conducted a key study to look at the ability 
of multifunctional liposomes to target Aβ. These liposomes 
were bi-functionalized with mApoE to enhance crossing 
of the BBB, and with phosphatidic acid (PA), which is a 
high affinity ligand for Aβ.61,71 This bifunctional liposome 
(mApoE-PA-LIP) was able to disaggregate Aβ fibrils in 
vitro, a property that was not exhibited by liposomes mono-
functionalized with either mApoE or PA alone. This syn-
ergistic effect could be due to simultaneous interaction of 
the negatively charged PA phosphate group with positively 
charged amino acid residues on Aβ and of positively charged 
amino acids on mApoE with negatively charged regions of 
Aβ.72 Results from in vivo studies, showing a reduction in 
amyloid plaque load only with mApoE-PA-LIP, are sup-
portive of this idea. However, the uptake of mApoE-PA-LIP 
in the brain was very low, despite the mApoE modification. 
Mancini et al conducted a follow-up investigation on the 
Table 2 Cell-penetrating peptides (CPPs) and their mechanism of internalization
CPP Mechanism Origin References




Pep-1 Pore formation Chimeric 111
Pep-7 Pore formation CHL8 peptide phage clone 112
pveC Transporter mediated Murine endothelial cadherin 113
Transportan endocytosis Galanin-mastoparan 114
Polyarginines Multiple mechanisms Chemically synthesized 108, 115
DPv1047 energy-dependent mechanisms, independent of GAGs  
(charge interactions, HSPH binding)
Chemically synthesized 116
MPG Pore formation HIv glycoprotein 41/Sv40 T  
antigen NLS
117
ARF endocytosis p14 ARF protein 118
p28 Caveolar-mediated/nonclathrin-caveolar-mediated Azurin 119
BPrPr Macropinocytosis (fluid-phase endocytosis) N terminus of unprocessed  
bovine prion protein
120
vT5 Non-specific endocytosis Chemically synthesized 121
Bac 7 Likely non-specific endocytosis Bactenecin family of antimicrobial  
peptides
122
C105Y energy-independent process via caveolin- and clathrin- 
independent lipid rafts
α1-Antitrypsin 123
PFvYLI energy-independent process via caveolin- and clathrin- 
independent lipid rafts
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mechanism behind this therapy, and a strategy known as 
the “sink effect” was proposed, which reduces Aβ burden 
by peripheral administration of a binding agent that draws 
excess Aβ out of the brain (Figure 3).73 The study showed that 
peripheral administration of mApoE-PA-LIP increased the 
level of plasma Aβ without significant amounts of mApoE-
PA-LIP entering the brain. Aβ oligomers were found to be 
transported out of the brain, across the BBB, with mApoE-
PA-LIP acting in the periphery to mediate a fivefold increase 
in this efflux.74
This provides an insight into future therapies that may 
only require sequestration of Aβ in the plasma, without the 
need to cross the BBB. It is evident, however, that this therapy 
might slow down neurodegeneration, but does not eliminate 
the cause of Aβ overproduction. Yet, this bifunctional lipo-
some system provides a valuable insight into future research 
that may effectively prevent amyloid plaque formation.
Curcumin-lipid liposomes
Oxidative damage occurs very early on in course of AD,75,76 
and antioxidants can protect neurons from β-amyloid 
toxicity,77 and so clinical trials involving antioxidants for the 
treatment of AD have been undertaken. So far, these have 
been unsuccessful,78 but the use of curcumin, a turmeric 
derivative, has shown some potential due to its anti-amyloid 
effects.79 This phenolic antioxidant binds to amyloid deposits 
in vitro and in vivo, and it not only disrupts the aggregation 
of the amyloid peptide but also disaggregates pre-formed 
fibrils.80,81 A curcumin analog with a substitution at the C-4 
position has been reported to be more effective in this regard 
than curcumin itself.82
Curcumin has relatively poor bioavailability, hence, lipo-
somal delivery systems for curcumin have been developed 
in an attempt to overcome this.83,84 In the curcumin-lipid 
modified liposome developed by Mourtas et al,84 a PEGylated 
lipid coating provides stealth characteristics and acts as an 
anchor allowing the attachment of anti-transferrin monoclo-
nal antibodies, for mediation of transport across the BBB, in 
addition to a lipid-PEG-curcumin derivative. Results showed 
that this system has high affinity for amyloid plaques and 
reduces amyloid plaque formation in APPswe transgenic 
mice.79 These liposomes may be useful in the future for the 
diagnosis and treatment of AD.
Peptide inhibitor nanoparticles (PINPs)
Austen et al85 showed that a small peptide, named OR2 
(RGKLVFFGR-NH
2
), inhibits the aggregation of Aβ into 
oligomers and fibrils, and blocks the toxic effects of Aβ 
on cultured cells. However, this peptide is sensitive to 
proteolysis and was not designed to cross the BBB.85 To 
improve its stability, a retro-inverso version (RI-OR2) was 
made,86 and this was enhanced further by the addition of a 




its peripheral injection, a fluorescein-labeled version of 
RI-OR2-TAT was found to cross the BBB and bind to the 
amyloid plaques present in the cerebral cortex of APPswe/
PS1ΔE9 transgenic mice. Daily intraperitoneal (ip) injection 
Figure 3 The sink effect strategy.
Notes: Aβ assemblies are in equilibrium between the brain and bloodstream, across the BBB endothelium. It is proposed that mApoE-PA modified liposomes sequester 
soluble Aβ (monomers or soluble oligomers) in the peripheral bloodstream, which is then cleared. This creates an imbalance of soluble Aβ. Transport of Aβ from the brain 
to the blood, across the BBB, is then favored, to restore this imbalance. This reduces Aβ burden in the brain and is coined the “sink effect.”



































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1




Liposome delivery for Alzheimer’s disease
of RI-OR2-TAT, for 3 weeks, into these mice resulted in sub-
stantial (25%–45%) reductions in brain Aβ oligomer levels, 
amyloid plaque counts, oxidative damage, and inflammatory 
processes. However, RI-OR2-TAT inhibits Aβ aggregation 
only at relatively high concentrations (ie, at a molar ratio 
of RI-OR2-TAT:Aβ of 1:5 at best) and so its therapeutic 
potential is likely to be limited.67
In order to improve RI-OR2-TAT further, it was 
attached to the surface of stealth liposomes by covalent 
linkage to the PEGylated lipid, via an additional cysteine 
residue on the peptide, to produce PINPs (Figure 4).65 
The presence of the liposome carrier greatly improves the 
potency of RI-OR2-TAT, so that a molar ratio of 1:2,000 of 
liposome-linked inhibitory peptide to Aβ now gives ~50% 
inhibition of Aβ aggregation. This great increase in potency 
could be due to a multivalent effect. Many copies of the 
RI-OR2-TAT decorate each liposome, which should allow 
the simultaneous interaction of multiple inhibitory peptides 
with any multimeric form of Aβ, thus increasing efficiency 
as an aggregation inhibitor. EM studies have shown that 
PINPs can attach themselves to the free ends of amyloid 
fibrils (Figure 5),87 apparently terminating fibril growth, 
Figure 4 Targeting strategy with PINPs.
Notes: PINPs transport across the BBB by non-specific endocytosis, triggered by positively charged TAT interaction with the negatively charged membrane. RI-OR2-TAT 
inhibitor acts to prevent the aggregation of Aβ into oligomers and fibrils.
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and possibly preventing the formation of Aβ oligomers 
(the free ends of fibrils act as “factories” for generation of 
oligomeric Aβ).88 Studies in transgenic mice have shown 
that peripheral injection of PINPs protects against memory 
loss in TG2576 mice.65 The TAT region of the inhibitory 
peptide facilitates brain penetration, with a brain:blood ratio 
of around 50% being achieved shortly after intravenous 
(iv) injection. However, most of the dose accumulates in 
peripheral tissues, such as lungs, liver, and spleen, most 
likely due to clearance of liposomes via the reticuloen-
dothelial system, and so it is possible that the “sink” effect 
(see above) could explain some of the in vivo properties of 
PINPs. The effectiveness of these PINPS could be improved 
in future by incorporation of alternative or additional brain 
delivery systems.
Neurotransmission targeting
Synaptic loss and degeneration in AD include the loss 
of brain cholinergic neurons, which results in decreased 
acetylcholine (ACh) levels, reduced ACh receptor (AChR) 
density, and an overall decrease in cholinergic neurotrans-
mission. Many limitations and side effects are associated 
with the existing AChEIs that attempt to rebalance cholin-
ergic neurotransmission in AD. They have poor stability in 
circulation, unpredictable uptake and bioavailability, and 
can cause gastrointestinal complications and, occasionally, 
even esophageal tears.89 They also provide only temporarily 
improved cognition. Yet, it may be worthwhile to improve 
these existing therapies, especially since viable alternatives 
have failed to emerge. Subsequently, studies have investi-
gated the potential use of multifunctionalized liposomes, 
incorporating existing drugs, to treat AD.
Rivastigmine-loaded liposomes
Rivastigmine is a reversible, noncompetitive inhibitor of 
brain acetylcholinesterase (AChE).90 As stated previously, 
oral rivastigmine administration has many limitations, such 
as poor stability and low ability to pass through the BBB. 
An alternative intranasal delivery route has shown some 
potential as an alternative for rivastigmine administration.91 
A study from Yang et al92 has considered whether intranasal 
delivery of liposomes loaded with rivastigmine can enhance 
brain delivery and improve therapeutic effect. These lipo-
somes were modified with a PEGylated derivative of a poly-
arginine CPP (DSPE-PEG-CPP) to increase stability and 
enhance BBB delivery, respectively, in an attempt to improve 
the limitations exhibited by the administration of rivastigmine 







Figure 5 Incubation of PINPs with Aβ.
Notes: Figure shows TeM images of negatively stained PINPs. (A) Individual PINPs before incubation with Aβ. (B) Individual PINPs after incubation with Aβ. (C) and (D) 
PINPs after extended incubation with Aβ bound to amyloid fibrils. Scale bars: A and B 150 nm, C and D 100 nm.
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effect of rivastigmine, due to enhanced transcytosis across 
both the BBB and cellular membranes.92
El-Helaly et al94 have reported an alternative modification 
strategy for the intranasal administration of rivastigmine-
loaded liposomes. In order to maintain their stability, a posi-
tively charged inducer called didecyldimethyl ammonium 
bromide was added to these liposomes, leading to electro-
static repulsion and reduced interactions between them. This, 
coupled with the use of a PEGylated lipid, resulted in a highly 
stabile “electrosteric stealth liposome.”93 Results showed a 
fourfold increase in both plasma and brain drug levels, com-
pared to rivastigmine itself. This effect was increased further 
with liposomes bound to Tween 80, a nonionic surfactant 
that has been found to enhance BBB transport.94 Tween 80 
is likely to act as an anchor for apolipoproteins (APO-E and 
APO-B), enhancing BBB transport via receptor-mediated 
endocytosis.95 Further preclinical studies on rivastigmine-
loaded liposomes are required, such as toxicity and dose–
response studies, before they can be considered as suitable 
for therapeutic use.
Liposomes with multiple 
therapeutic targets
Liposomes have great potential for modification, includ-
ing the development of multifunctional liposomes directed 
against more than one therapeutic target. In the case of AD, 
one of the legitimate goals would be to target the formation 
of both Aβ plaques and tau tangles. Theoretically, it is pos-
sible to conceive of a multifunctional liposome that also 
incorporates other therapeutics, such as those directed at the 
ACh system, neuroprotectants, autophagy, anti-inflammatory 
agents, or antioxidants.
wheat germ agglutinin-conjugated 
liposomes
The multifunctional liposomes produced by Kuo et al aim to 
improve the overall neuronal survival in AD by inhibiting the 
phosphorylation of p38 and c-Jun N-terminal kinase (JNK), 
two key members of the mitogen-activated protein kinase 
(MAPK) family, in neurons damaged by the accumulation 
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Figure 6 Cell survival and apoptotic pathway in AD therapy.
Notes: Action of wGA-CRM-CL/LIPs: Curcumin inhibits phosphorylation of JNK and p38, preventing downstream phosphorylation of tau serine 202, leading to prevention 
of apoptotic neurodegeneration. NGF binds TrkA and mediates MAPK phosphorylation cascade and recruitment of CReB, enhancing overall cell survival.
Abbreviations: CL, cardiolipin; CReB, cAMP response element binding protein; CRM, curcumin; JNK, c-Jun N-terminal kinase; LIPs, liposomes; MAPK, mitogen-activated 
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for the understanding of AD progression, since MAPK-
catalyzed phosphorylation events in the brain have a key 
role in the downstream activity of cellular components (eg, 
phosphatases, kinases) that impact on apoptosis and overall 
neuronal survival. It would also provide valuable insight into 
possible future therapies.
The key constituents of this multifunctional liposome 
(coined WGA-CRM-CL/LIP) are curcumin (CRM), nerve 
growth factor (NGF), cardiolipin (CL), and wheat germ 
agglutinin (WGA). In addition to acting as an Aβ aggregation 
inhibitor, curcumin alters the expression of phosphorylated 
p38 (p-p38) and phosphorylated c-Jun N-terminal kinase 
(p-JNK), key players in the apoptotic pathway. NGF pro-
motes the activity of tyrosine kinase receptor type 1 (TrkA), 
which is involved in slowing down neuronal apoptosis. In 
order to enhance the targeting of apoptotic neurons sur-
rounding Aβ, CL was included, as it has a strong affinity 
for Aβ. In this case, both PEGylation and WGA provided 
an additional novel dual functionalization, with the aim of 
improving delivery across the BBB.42
WGA-CRM-CL/LIPs reduced Aβ “plaque” deposition in 
AD model SK-N-MC cells and increased the percentage of 
healthy neurons with cholinergic activity in a Wistar rat AD 
model (established by injection of Aβ into CA1 neurons). 
Additionally, curcumin mediates downstream inhibition of 
tau phosphorylation at serine 202, which is a key site for 
axonogenesis (Figure 6).96 While the therapeutic potential 
of this inhibition is unclear, this is an illustrative method 
of targeting and altering tau phosphorylation, while also 
targeting and reducing Aβ burden. The authors suggest that 
WGA-CRM-CL/LIP should have little effect on a healthy 
brain, since it is not in an inflammatory state and that this 
type of AD therapy would most likely be given to patients 
in the later stages of AD.42
Aβ targeting nanosweepers
Luo et al97 have developed “nanosweepers” (M
3
) that not 
only capture extracellular Aβ and direct it into cells but also 
upregulate autophagy and digestion of Aβ. The nanosweep-
ers are composed of a cationic chitosan core with PEGylated 
GKLVFF (that can co-assemble with Aβ) and Becln-1 (that 
induces autophagy to degrade Aβ). They work by capturing 
and co-assembling with extracellular Aβ, inhibiting toxic Aβ 
formation, then specifically directing Aβ into cells and acti-
vating autophagy. This strategy has been shown to degrade 
insoluble Aβ from a level of 1,539 down to 914 ng/mg, and 
soluble Aβ from 585 to 190 ng/mg, in APPswe/PS1dE9 
transgenic mice, and also increase neuronal cell viability. 
M
3
 is a multifunctional peptide-polymer that could provide 
a novel therapeutic approach for the treatment of AD, by 
clearance of Aβ.97 By design, it is not a good aggregation 
inhibitor and could be useful in combination with additional 
therapies.
Future prospects
The majority of studies employing liposomal carrier systems 
to target the CNS are still restricted to early experimental 
work on cell and animal models, or follow on preclinical 
development, with none so far entering human clinical trials. 
Further investment and research is required to develop and 
optimize these carrier systems for AD therapy, since many 
of the studies considered in this article report promising find-
ings, with a drive toward early clinical testing. A reoccurring 
problem is that some of the modifications on their own do not 
allow sufficient penetration through the BBB, or adequate tar-
geting for AD therapy. Since liposomes have great potential 
for heavy functionalization, future steps should incorporate 
several different modifications into the same liposomes that 
can work together in synergy.
Furthermore, current systems in development have tended 
to target only Aβ, due to its fundamental role in AD, yet 
liposomes have the potential to be adapted to incorporate 
a therapeutic cocktail of molecules that aid BBB transport 
and are able to treat multiple areas of AD pathology. Fur-
ther studies could prevent the formation of tau tangles, by 
using an anti-tau antibody, or tau-directed peptides, or small 
molecule inhibitors, in addition to preventing formation 
or dissolution of amyloid plaques, and targeting of phos-
phorylation cascades. A therapeutic system that can target 
Aβ, tau, neuronal survival, and apoptosis, and cholinergic 
neurotransmission, for example, could become the gold 
standard treatment for AD; liposomes are certainly a good 
candidate for the development of such a therapy. CPPs have 
great potential for AD therapy, yet their non-specific uptake 
by peripheral tissue limits their use. TAT peptide, which 
is derived from HIV, is an example of utilizing aspects of 
pathogens for therapeutic purposes. The future of CPPs for 
brain delivery could involve using trans-membrane peptide 
domains derived from trypanosomes,98 or the Zika virus,99 
both of which contain peptides that target enhanced uptake 
into the brain.
Drawbacks and barriers
There remain some issues for liposomes as a drug delivery 
system. There is an increased cost when they are used, but 
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to reach its target with a liposome, but not without, or the 
overall dose may be decreased as a greater proportion of the 
drug reaches its target. They are not suitable for oral delivery 
because they will rupture due to osmotic shock when entering 
the hypotonic environment of the stomach (depending on the 
osmolarity of the internal aqueous filling of the liposome) 
and the lipids will be digested in the small intestine. Once 
in the bloodstream, the majority of liposomes are taken up 
non-specifically by the mononuclear phagocyte system, and 
this includes those with a stealth coating. This reduces the 
number available to be delivered to the brain, although this 
can be overcome by administering a larger dose in a single 
bolus, rather than multiple smaller doses.100 There are two 
main strategies for crossing the BBB (see “BBB transport” 
section) by either targeting a transporter system or by use of 
a CPP. The former approach may lead to saturation of the 
transporter system, whereas this is less of a limiting factor 
in the latter as it is non-specific. Finally, as this is a rela-
tively new technology, there are still some technical issues 
regarding the supply of liposome products to the consumer 
in terms of sterility and product shelf life. Liposomes are 
not suitable for heat sterilization, but bacterial contamina-
tion can be avoided by filtration due to the small size of the 
liposomes.101 In terms of stability, liposomes in suspension 
will eventually start to fuse together, changing the size to the 
point at which they become ineffective as a delivery system. 
To avoid this, the liposomes can be lyophilized or spray dried 
in the presence of trehalose or sucrose and will retain their 
size on rehydration.102,103
Conclusion
Despite these challenges, the use of liposomal carriers is 
proving to be a potentially good strategy for future therapy 
of AD. They have a unique ability for modification to cross 
the BBB, while also showing some evidence of effective-
ness without brain delivery, via the peripheral sink effect. 
Multiple molecules are able to enhance BBB transport, and 
many others allow targeting toward key molecular systems 
involved in AD pathogenesis. It is likely that future develop-
ment will focus mainly on early intervention to slow down the 
progression of this disease, rather than attempting to reverse 
it in more advanced cases. Current study is moving toward 
targeting more than just one aspect of brain pathology, using 
multifunctional liposomes, and this holds great promise for 
the future, but is currently in the very early stages of develop-
ment. Further study and substantial funding will be required 
to achieve success, so that this type of strategy can be driven 
into human clinical trials and beyond.
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